{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:52:24Z","timestamp":1776271944747,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Left ventricular ejection fraction (LVEF) trajectories and functional recovery with current heart failure (HF) management is increasingly recognized. Type 2 diabetes mellitus (T2D) leads to a worse prognosis in HF patients. However, it is unknown whether T2D interferes with LVEF trajectories. The aim of this study was to prospectively assess very long-term (up to 15\u00a0years) LVEF trajectories in patients with and without T2D and underlying HF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ambulatory patients admitted to a multidisciplinary HF clinic were prospectively evaluated by scheduled two-dimensional echocardiography at baseline, 1\u00a0year, and then every 2\u00a0years afterwards, up to 15\u00a0years. Statistical analyses of LVEF change with time were performed using the linear mixed effects (LME) models, and locally weighted error sum of squares (Loess) curves were plotted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 1921 patients, 461 diabetic and 699 non-diabetic patients with LVEF\u2009&lt;\u200950% were included in the study. The mean number of echocardiography measurements performed in diabetic patients was 3.3\u2009\u00b1\u20091.6. Early LVEF recovery was similar in diabetic and non-diabetic patients, but Loess curves showed a more pronounced inverted U shape in diabetics with a more pronounced decline after 9\u00a0years. LME analysis showed a statistical interaction between T2D and LVEF trajectory over time (p\u2009=\u20090.009), which was statistically significant in patients with ischemic etiologies (p\u2009&lt;\u20090.001). Other variables that showed an interaction between LVEF trajectories and T2D were male sex (p\u2009=\u20090.04) and HF duration (p\u2009=\u20090.008).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>LVEF trajectories in T2D patients with depressed systolic function showed a pronounced inverted U shape with a marked decline after 9\u00a0years. Diabetic cardiomyopathy may underlie the functional decline observed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-020-01011-w","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T16:05:06Z","timestamp":1584979506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline"],"prefix":"10.1186","volume":"19","author":[{"given":"Mar\u00eda Teresa","family":"Juli\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00faria","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Lup\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovana","family":"Gavidia-Bovadilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"de Antonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"L\u00f3pez-Ayerbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Santiago-Vacas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pau","family":"Codina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Moliner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Santesmases","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"issue":"62","key":"1011_CR1","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"2013","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;2013(62):e147\u2013239.","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"1011_CR2","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"14","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Falk V, Authors\/Task Force Members, Document Reviewers, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;14(37):2129\u2013200.","journal-title":"Eur Heart J."},{"key":"1011_CR3","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","volume":"241","author":"WB Kannel","year":"1979","unstructured":"Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035\u20138.","journal-title":"JAMA"},{"key":"1011_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ehj.2004.01.010","volume":"25","author":"P De Groote","year":"2004","unstructured":"De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E, Bauter C. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J. 2004;25:656\u201362.","journal-title":"Eur Heart J"},{"key":"1011_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u201344.","journal-title":"N Engl J Med"},{"key":"1011_CR6","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377\u201385.","journal-title":"Eur Heart J."},{"key":"1011_CR7","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/S0002-9149(97)89163-1","volume":"77","author":"DM Shindler","year":"1996","unstructured":"Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77:1017\u201320.","journal-title":"Am J Cardiol"},{"key":"1011_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","volume":"3","author":"A Dei Cas","year":"2015","unstructured":"Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015;3:136\u201345.","journal-title":"JACC Heart Fail"},{"key":"1011_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1002\/ejhf.824","volume":"19","author":"J Lup\u00f3n","year":"2017","unstructured":"Lup\u00f3n J, D\u00edez-L\u00f3pez C, de Antonio M, Domingo M, Zamora E, Moliner P, et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail. 2017;19:1615\u201323.","journal-title":"Eur J Heart Fail"},{"key":"1011_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jacc.2018.05.042","volume":"72","author":"J Lup\u00f3n","year":"2018","unstructured":"Lup\u00f3n J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, L\u00f3pez-Ayerbe J, et al. Dynamic trajectories of left ventricular ejection fraction in heart failure. J Am Coll Cardiol. 2018;72:591\u2013601.","journal-title":"J Am Coll Cardiol"},{"key":"1011_CR11","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.jacc.2011.11.066","volume":"59","author":"E Zamora","year":"2012","unstructured":"Zamora E, Lup\u00f3n J, Vila J, et al. Estimated glomerular filtration rate and prognosis in heart failure: value of the modification of diet in renal disease study-4, chronic kidney disease epidemiology collaboration, and cockroft-gault formulas. J Am Coll Cardiol. 2012;59:1709\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"1011_CR12","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.2337\/dc15-S005","volume":"38","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2015;38(Suppl 1):S8\u201316.","journal-title":"Diabetes Care"},{"key":"1011_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/01621459.1988.10478639","volume":"83","author":"WS Cleveland","year":"1988","unstructured":"Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc. 1988;83:596\u2013610.","journal-title":"J Am Stat Assoc"},{"key":"1011_CR14","unstructured":"Bates DM. lme4: mixed-effects modeling with R. Springer, 2010. http:\/\/lme4.rforge.r-project.org\/. Accessed Jan 2016."},{"key":"1011_CR15","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1198\/jasa.2001.s411","volume":"96","author":"VJ Carey","year":"2001","unstructured":"Carey VJ, Wang Y-G. Book review: mixed-effects models in S and S-plus. J Am Stat Assoc. 2001;96:1135.","journal-title":"J Am Stat Assoc"},{"key":"1011_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-019-0883-4","volume":"18","author":"B Zareni","year":"2019","unstructured":"Zareni B, R\u00f8rth R, Mogensen UM, Selmer C, Gislason G, Torp-Pedersen C. Heart failiure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study. Cardiovasc Diabetol. 2019;18:79.","journal-title":"Cardiovasc Diabetol"},{"key":"1011_CR17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1161\/CIRCHEARTFAILURE.111.966366","volume":"5","author":"SM Dunlay","year":"2012","unstructured":"Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012;5:720\u20136.","journal-title":"Circ Heart Fail"},{"key":"1011_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/CIRCHEARTFAILURE.113.000813","volume":"7","author":"P de Groote","year":"2014","unstructured":"de Groote P, Fertin M, Duva Pentiah A, Go\u00e9minne C, Lamblin N, Bauters C. Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after \u03b2-blocker therapy. Circ Heart Fail. 2014;7:434\u20139.","journal-title":"Circ Heart Fail"},{"key":"1011_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cardfail.2003.10.002","volume":"10","author":"G Cioffi","year":"2004","unstructured":"Cioffi G, Stefenelli C, Tarantini L, Opasich C. Chronic left ventricular failure in the community: prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy. J Card Fail. 2004;10:250\u20137.","journal-title":"J Card Fail"},{"key":"1011_CR20","doi-asserted-by":"publisher","first-page":"e001504","DOI":"10.1161\/JAHA.114.001504","volume":"4","author":"M Merlo","year":"2015","unstructured":"Merlo M, Stolfo D, Anzini M, et al. Persistent recovery of normal left ventricular function and dimension in idiopathic dilated cardiomyopathy during long-term follow-up: does real healing exist? J Am Heart Assoc. 2015;4:e001504.","journal-title":"J Am Heart Assoc"},{"key":"1011_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1210\/er.2003-0012","volume":"25","author":"ZY Fang","year":"2004","unstructured":"Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25:543\u201367.","journal-title":"Endocr Rev"},{"key":"1011_CR22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1161\/01.CIR.0000012467.61045.87","volume":"105","author":"ME Young","year":"2002","unstructured":"Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaption of the heart in diabetes: part II: potential mechanism. Circulation. 2002;105:1861\u201370.","journal-title":"Circulation"},{"key":"1011_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12933-019-0842-0","volume":"18","author":"D Modin","year":"2019","unstructured":"Modin D, M\u00f8gelvang R, J\u00f8rgensen PG, Jensen MT, Seferovic JP, Biering-S\u00f8rensen T. Left ventricular concentric geometry predicts incident diabetes mellitus independent of established risk factors in the general population: the Copenhagen City Heart Study. Cardiovasc Diabetol. 2019;18:37.","journal-title":"Cardiovasc Diabetol"},{"key":"1011_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.11.087","author":"J Gu","year":"2019","unstructured":"Gu J, Yin ZF, Zhang JF, Wang CQ. Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension. Int J Cardiol. 2019. https:\/\/doi.org\/10.1016\/j.ijcard.2019.11.087.","journal-title":"Int J Cardiol"},{"key":"1011_CR25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","volume":"90","author":"GD Lopaschuk","year":"2010","unstructured":"Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metablism in health and disease. Physiol Rev. 2010;90:207\u201358.","journal-title":"Physiol Rev"},{"key":"1011_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0735-1097(01)01408-5","volume":"38","author":"DL Dries","year":"2001","unstructured":"Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol. 2001;38:421\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1011_CR27","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0735-1097(03)00856-8","volume":"42","author":"M Domanski","year":"2003","unstructured":"Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42:914\u201322.","journal-title":"J Am Coll Cardiol"},{"key":"1011_CR28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.jacc.2016.06.061","volume":"68","author":"I Johansson","year":"2016","unstructured":"Johansson I, Dahlstr\u00f6m U, Edner M, N\u00e4sman P, Ryd\u00e9n L, Norhammar A. Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J Am Coll Cardiol. 2016;68:1404\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"1011_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","volume":"104","author":"FM Hasan","year":"2014","unstructured":"Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297\u2013322.","journal-title":"Diabetes Res Clin Pract"},{"key":"1011_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","volume":"13","author":"B Lin","year":"2014","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.","journal-title":"Cardiovasc Diabetol"},{"key":"1011_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","volume":"18","author":"N Zhang","year":"2019","unstructured":"Zhang N, Feng B, Ma X, Sun K, Xu G, Zhou Y. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2019;18:107.","journal-title":"Cardiovasc Diabetol"},{"key":"1011_CR32","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1011_CR33","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"1011_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"1011_CR35","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"38","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;38:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"1011_CR36","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108\u201317.","journal-title":"Diabetologia"},{"key":"1011_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2019.07.010","author":"I Oriol","year":"2019","unstructured":"Oriol I, Santiago-Vacas E, Yurista S, Lup\u00f3n P, Packer M, Heymans S, et al. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC Basic Transl Sci. 2019. https:\/\/doi.org\/10.1016\/j.jacbts.2019.07.010.","journal-title":"JACC Basic Transl Sci"},{"key":"1011_CR38","first-page":"1","volume":"2","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in N-Terminal Pro-B-Type natriuretic peptide following initiation of sacubitril\u2013valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;2:1\u201311.","journal-title":"JAMA"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-020-01011-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-01011-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:14:18Z","timestamp":1616458458000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-01011-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-01011-w","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"11 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants gave their informed consent, and this study was performed in compliance with the Helsinki Declaration, and was approved by the local Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}